Comparative efficacy of biologics in psoriasis

A review

Iris H. Kim, Cameron E. West, Shawn Kwatra, Steven R. Feldman, Jenna L. O'Neill

Research output: Contribution to journalReview article

Abstract

Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Safe and effective long-term treatments are needed. Biologic treatments that inhibit the immunopathogenesis of psoriasis have helped meet this need. Purpose: The purpose of this study was to compare the efficacy of biologic therapies used for psoriasis. Methods: A literature search was performed using PubMed and the keywords '(PASI-75 OR efficacy) AND psoriasis AND (adalimumab OR alefacept OR etanercept OR infliximab OR ustekinumab).' Randomized, double-blind, and placebo-controlled studies on US FDA-approved biologics were selected. Studies assessing the proportion of subjects achieving 75%improvement in PsoriasisArea and Severity Index (PASI-75) within a 12-week period were included. Studies on pediatric populations and psoriatic arthritis were excluded. The weighted average of PASI-75 for each reported regimen was calculated to determine the efficacy of biologic agents used for moderate-to-severe psoriasis. Tolerance and secondary efficacy measures were also examined for the selected studies. Results: FDA-approved regimens of adalimumab, infliximab, ustekinumab, and alefacept were effective in treating moderate-to-severe psoriasis. Weighted average PASI-75 scores for infliximab, ustekinumab, adalimumab, etanercept, and alefacept were 78.6%, 72.1%, 70.5%, 48.1%, and 21%, respectively. Limitations: The comparative efficacy of biologic agents data was limited to 12 weeks, thus generalizing the results to longer treatment periods may not be accurate. Conclusions: Various biologic agents for psoriasis were effective at 12 weeks in placebo-controlled trials. Available data cannot fully account for situations in clinical practice, in which combination and longer duration of therapy may be required. When choosing the most effective or best agent, multiple factors should be considered including patient preference, cost, tolerance, adverse effects, dosing schedule, andmode of administration. Adis

Original languageEnglish (US)
Pages (from-to)365-374
Number of pages10
JournalAmerican Journal of Clinical Dermatology
Volume13
Issue number6
DOIs
StatePublished - Oct 18 2012
Externally publishedYes

Fingerprint

Biological Products
Psoriasis
Biological Factors
Placebos
Psoriatic Arthritis
Biological Therapy
Patient Preference
Therapeutics
Skin Diseases
PubMed
Appointments and Schedules
Pediatrics
Costs and Cost Analysis
Population
alefacept
Ustekinumab
Adalimumab
Infliximab

Keywords

  • Adalimumab
  • Alefacept
  • Biological-products
  • Etanercept
  • Infliximab
  • Psoriasis
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Comparative efficacy of biologics in psoriasis : A review. / Kim, Iris H.; West, Cameron E.; Kwatra, Shawn; Feldman, Steven R.; O'Neill, Jenna L.

In: American Journal of Clinical Dermatology, Vol. 13, No. 6, 18.10.2012, p. 365-374.

Research output: Contribution to journalReview article

Kim, Iris H. ; West, Cameron E. ; Kwatra, Shawn ; Feldman, Steven R. ; O'Neill, Jenna L. / Comparative efficacy of biologics in psoriasis : A review. In: American Journal of Clinical Dermatology. 2012 ; Vol. 13, No. 6. pp. 365-374.
@article{08883a9de43d4c22b15bb0a511be4a54,
title = "Comparative efficacy of biologics in psoriasis: A review",
abstract = "Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Safe and effective long-term treatments are needed. Biologic treatments that inhibit the immunopathogenesis of psoriasis have helped meet this need. Purpose: The purpose of this study was to compare the efficacy of biologic therapies used for psoriasis. Methods: A literature search was performed using PubMed and the keywords '(PASI-75 OR efficacy) AND psoriasis AND (adalimumab OR alefacept OR etanercept OR infliximab OR ustekinumab).' Randomized, double-blind, and placebo-controlled studies on US FDA-approved biologics were selected. Studies assessing the proportion of subjects achieving 75{\%}improvement in PsoriasisArea and Severity Index (PASI-75) within a 12-week period were included. Studies on pediatric populations and psoriatic arthritis were excluded. The weighted average of PASI-75 for each reported regimen was calculated to determine the efficacy of biologic agents used for moderate-to-severe psoriasis. Tolerance and secondary efficacy measures were also examined for the selected studies. Results: FDA-approved regimens of adalimumab, infliximab, ustekinumab, and alefacept were effective in treating moderate-to-severe psoriasis. Weighted average PASI-75 scores for infliximab, ustekinumab, adalimumab, etanercept, and alefacept were 78.6{\%}, 72.1{\%}, 70.5{\%}, 48.1{\%}, and 21{\%}, respectively. Limitations: The comparative efficacy of biologic agents data was limited to 12 weeks, thus generalizing the results to longer treatment periods may not be accurate. Conclusions: Various biologic agents for psoriasis were effective at 12 weeks in placebo-controlled trials. Available data cannot fully account for situations in clinical practice, in which combination and longer duration of therapy may be required. When choosing the most effective or best agent, multiple factors should be considered including patient preference, cost, tolerance, adverse effects, dosing schedule, andmode of administration. Adis",
keywords = "Adalimumab, Alefacept, Biological-products, Etanercept, Infliximab, Psoriasis, Ustekinumab",
author = "Kim, {Iris H.} and West, {Cameron E.} and Shawn Kwatra and Feldman, {Steven R.} and O'Neill, {Jenna L.}",
year = "2012",
month = "10",
day = "18",
doi = "10.2165/11633110-000000000-00000",
language = "English (US)",
volume = "13",
pages = "365--374",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Comparative efficacy of biologics in psoriasis

T2 - A review

AU - Kim, Iris H.

AU - West, Cameron E.

AU - Kwatra, Shawn

AU - Feldman, Steven R.

AU - O'Neill, Jenna L.

PY - 2012/10/18

Y1 - 2012/10/18

N2 - Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Safe and effective long-term treatments are needed. Biologic treatments that inhibit the immunopathogenesis of psoriasis have helped meet this need. Purpose: The purpose of this study was to compare the efficacy of biologic therapies used for psoriasis. Methods: A literature search was performed using PubMed and the keywords '(PASI-75 OR efficacy) AND psoriasis AND (adalimumab OR alefacept OR etanercept OR infliximab OR ustekinumab).' Randomized, double-blind, and placebo-controlled studies on US FDA-approved biologics were selected. Studies assessing the proportion of subjects achieving 75%improvement in PsoriasisArea and Severity Index (PASI-75) within a 12-week period were included. Studies on pediatric populations and psoriatic arthritis were excluded. The weighted average of PASI-75 for each reported regimen was calculated to determine the efficacy of biologic agents used for moderate-to-severe psoriasis. Tolerance and secondary efficacy measures were also examined for the selected studies. Results: FDA-approved regimens of adalimumab, infliximab, ustekinumab, and alefacept were effective in treating moderate-to-severe psoriasis. Weighted average PASI-75 scores for infliximab, ustekinumab, adalimumab, etanercept, and alefacept were 78.6%, 72.1%, 70.5%, 48.1%, and 21%, respectively. Limitations: The comparative efficacy of biologic agents data was limited to 12 weeks, thus generalizing the results to longer treatment periods may not be accurate. Conclusions: Various biologic agents for psoriasis were effective at 12 weeks in placebo-controlled trials. Available data cannot fully account for situations in clinical practice, in which combination and longer duration of therapy may be required. When choosing the most effective or best agent, multiple factors should be considered including patient preference, cost, tolerance, adverse effects, dosing schedule, andmode of administration. Adis

AB - Background: Psoriasis is a chronic, immune-mediated skin disease that also has systemic manifestations. Safe and effective long-term treatments are needed. Biologic treatments that inhibit the immunopathogenesis of psoriasis have helped meet this need. Purpose: The purpose of this study was to compare the efficacy of biologic therapies used for psoriasis. Methods: A literature search was performed using PubMed and the keywords '(PASI-75 OR efficacy) AND psoriasis AND (adalimumab OR alefacept OR etanercept OR infliximab OR ustekinumab).' Randomized, double-blind, and placebo-controlled studies on US FDA-approved biologics were selected. Studies assessing the proportion of subjects achieving 75%improvement in PsoriasisArea and Severity Index (PASI-75) within a 12-week period were included. Studies on pediatric populations and psoriatic arthritis were excluded. The weighted average of PASI-75 for each reported regimen was calculated to determine the efficacy of biologic agents used for moderate-to-severe psoriasis. Tolerance and secondary efficacy measures were also examined for the selected studies. Results: FDA-approved regimens of adalimumab, infliximab, ustekinumab, and alefacept were effective in treating moderate-to-severe psoriasis. Weighted average PASI-75 scores for infliximab, ustekinumab, adalimumab, etanercept, and alefacept were 78.6%, 72.1%, 70.5%, 48.1%, and 21%, respectively. Limitations: The comparative efficacy of biologic agents data was limited to 12 weeks, thus generalizing the results to longer treatment periods may not be accurate. Conclusions: Various biologic agents for psoriasis were effective at 12 weeks in placebo-controlled trials. Available data cannot fully account for situations in clinical practice, in which combination and longer duration of therapy may be required. When choosing the most effective or best agent, multiple factors should be considered including patient preference, cost, tolerance, adverse effects, dosing schedule, andmode of administration. Adis

KW - Adalimumab

KW - Alefacept

KW - Biological-products

KW - Etanercept

KW - Infliximab

KW - Psoriasis

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84867424597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867424597&partnerID=8YFLogxK

U2 - 10.2165/11633110-000000000-00000

DO - 10.2165/11633110-000000000-00000

M3 - Review article

VL - 13

SP - 365

EP - 374

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 6

ER -